Retroviral-vector-mediated gene therapy to mucopolysaccharidosis i mice improves sensorimotor impairments and other behavioral deficits

Journal of Inherited Metabolic Disease

Volumn 36, Issue 3, 2013, Pages 499-512

  Baldo, Guilherme ^a,b   Wozniak, David F ^a   Ohlemiller, Kevin K ^a   Zhang, Yanming ^a   Giugliani, Roberto ^b   Ponder, Katherine P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

LEVO IDURONIDASE; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; ENZYME BLOOD LEVEL; GENE INACTIVATION; GENE THERAPY; HURLER SYNDROME; LONG TERMINAL REPEAT; LYSOSOME STORAGE DISEASE; MOUSE; NEWBORN; NONHUMAN; SENSORIMOTOR FUNCTION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANIMALS, NEWBORN; BEHAVIOR, ANIMAL; BRAIN; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; IDURONIDASE; MENTAL DISORDERS; MICE; MICE, INBRED C57BL; MOTOR NEURON DISEASE; MOTOR NEURONS; MUCOPOLYSACCHARIDOSIS I; RETROVIRIDAE;

EID: 84877765657     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9530-x     Document Type: Article

References (41)

1. Aldenhoven M, Boelens JJ, de Koning TJ (2008) The Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation. Biol Blood Marrow Transplant 14:485-498
2. Aronovich EL, Bell JB, Khan SA et al (2009) Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 17:1136-1144
3. Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011-1017
4. Baldo G, Wu S, Howe R et al (2011) Pathogenesis of aortic dilatation in MPS VII mice may involve complement activation. Mol Genet Metab 104:608-619
5. Banks WA (2004) Are the extracellular pathways a conduit for the delivery of therapeutics to the brain. Curr Pharm Des 10:1365-1370
6. Chung S, Ma X, Liu Y, Lee D, Tittiger M, Ponder KP (2007) Effect of neonatal administration of a retroviral vector expressing alpha-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab 90:181-192
7. Ciron C, Desmaris N, Colle MA et al (2006) Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol 60:204-213
8. Di Domenico C, Di Napoli D, Gonzalez Y et al (2006) Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum Gene Ther 17:1112-1121
9. Ellinwood NM, Ausseil J, Desmaris N et al (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19:251-259
10. Fuller GN, Burger PC (2007) Central nervous system. In: Mills S (ed) Histology for Pathologists, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 273-319
11. Garbuzova-Davis S, Louis MK, Haller EM, Derasari HM, Rawls AE, Sanberg PR (2011) Blood-brain barrier impairment in an animal model of MPS III B. PLoS One 6:e16601
12. Grubb JH, Vogler C, Levy B, Galvin N, Tan Y, Sly WS (2008) Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 105:2616-2621
13. Hartung SD, Frandsen JL, Pan D et al (2004) Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9:866-875
14. Heldermon CD, Hennig AK, Ohlemiller KK et al (2007) Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PLoS One 2:e772
15. Kakkis ED, Muenzer J, Tiller GE et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344:182-188
16. Kobayashi H, Carbonaro D, Pepper K et al (2005) neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 11:776-789
17. Liu Y, Xu L, Hennig AK et al (2005) Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol Ther 11:35-47
18. Ma X, Liu Y, Tittiger M et al (2007) Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol Ther 15:889-902
19. Metcalf J, Ma X, Linders B, Wu S et al (2010) A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice. Mol Ther 18:334-342
20. Neufeld EF, Muenzer J (2001) The Mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) Metabolic and Molecular Basis of Inherited Disease. McGraw Hill, New York, pp 3421-3452
21. Ohlemiller KK, Hennig AK, Lett JM, Heidbreder AF, Sands MS (2002) Inner ear pathology in the mucopolysaccharidosis VII mouse. Hear Res 16:969-984
22. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100:1902-1907
23. Osborne MJ, McElmurry RT, Lees CJ et al (2011) Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther 19:450-460
24. Pan D, Sciascia A, Vorhees C, Williams MT (2008) Progression of multiple behavior deficits with various age of onsets in a murine model of Hurler syndrome. Brain Res 1188:241-253
25. Ponder KP, Haskins ME (2007) Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7:1333-1345
26. -/- mice, a genetic model of mucopolysaccharidosis type I. Brain Res 1076:225-230
27. Reolon GK, Reinke A, de Oliveira MR et al (2009) Alterations in oxidative markers in the cerebellum and peripheral organs in MPS I mice. Cell Mol Neurobiol 29:443-448
28. Schachern PA, Cureoglu S, Tsuprun V, Paparella MM, Whitley CB (2007) Age-related functional and histopathological changes of the ear in the MPS I mouse. Int J Pediatr Otorhinolaryngol 71:197-203
29. Staba SL, Escolar ML, Poe M et al (2004) Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350:1960-1969
30. Thomas JA, Beck M, Clarke JT, Cox GF (2010) Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis I. J Inherit Metab Dis 33:421-427
31. Trobridge GD (2011) Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther 11:581-593
32. Visigalli I, Delai S, Politi LS et al (2010) Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116:5130-5139
33. Vogler C, Levy B, Grubb JH et al (2005) Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 102:14777-14782
34. Walkley SU (2004) Secondary accumulation of gangliosides in lysosomal storage disorders. Semin Cell Dev Biol 15:433-444
35. Wang D, Zhang W, Kalfa TA et al (2009a) Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci USA 106:19958-19963
36. Wang RY, Cambray-Forker EJ, Ohanian K et al (2009b) Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol Genet Metab 98:406-411
37. Watson G, Bastacky J, Belichenko P et al (2006) Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther 13:917-925
38. Wolf DA, Lenander AW, Nan Z et al (2011) Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis 43:123-133
39. Wozniak DF, Hartman RE, Boyle MP et al (2004) Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults. Neurobiol Dis 17:403-414
40. Wozniak DF, Xiao M, Xu L, Yamada KA, Ornitz DM (2007) Impaired spatial learning and defective theta burst induced LTP in mice lacking fibroblast growth factor 14. Neurobiol Dis 26:4-26
41. Wraith JE, Beck M, Lane R et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 120:e37-e46